BCM
CHRS icon

Bronte Capital Management’s Coherus Oncology CHRS Stock Holding History

Bronte Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.4K Sell
15,262
-4,020
-21% -$6.56K ﹤0.01% 55
2026
Q1 		$32.6K Hold
19,282
– – ﹤0.01% 46
2025
Q4 		$27.4K Buy
+19,282
New +$28.1K ﹤0.01% 37

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Bronte Capital Management's CHRS Position: Q2 2026 in Review

Bronte Capital Management reduced its Coherus Oncology (CHRS) stake by 21% in Q2 2026, selling an estimated $6.56K and leaving 15,262 shares worth $21.4K. The position accounts for ﹤0.01% of the portfolio, ranked #55.

Bronte Capital Management first reported a position in CHRS in Q4 2025 and has held it in 3 quarters since. The position peaked at $32.6K in Q1 2026. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Bronte Capital Management held 15,262 shares of Coherus Oncology worth $21.4K as of Q2 2026.
  • Bronte Capital Management sold 4,020 Coherus Oncology shares in Q2 2026, an estimated $6.56K.
  • Coherus Oncology made up ﹤0.01% of Bronte Capital Management's portfolio in Q2 2026, its #55 holding.
  • Bronte Capital Management first reported a position in Coherus Oncology in Q4 2025 and has held it in 3 quarters since.
  • Bronte Capital Management's Coherus Oncology position peaked at $32.6K in Q1 2026.
  • 146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Bronte Capital Management's 13F filing for Q2 2026, filed 5 Aug 2026.